Most people with myasthenia gravis start noticing improvement within about 3 to 5 days of beginning IVIg, with the strongest benefit arriving around one to two weeks after the infusion course starts. That said, the timeline varies from person to person, and some factors can shift how quickly and how well you respond.
When Improvement Typically Begins
In clinical studies, the median onset of improvement was 3 days after starting IVIg, though the range stretched from as early as 1 day to as late as 12 days. A separate study of 23 treatment courses found that satisfactory improvement began at about 4.3 days on average. So while a few people feel meaningfully better within the first day or two, most should expect to wait roughly 3 to 5 days before noticing that breathing feels easier, swallowing improves, or limb strength returns.
This is faster than most long-term immunosuppressive medications used for myasthenia gravis, which can take weeks or months to show results. That speed is exactly why IVIg is used in urgent situations.
When You’ll Feel the Full Effect
Peak benefit, the point where you’re as strong as this treatment course is going to make you, typically arrives about 7 to 8 days after starting the infusion. One study reported a median peak at 7 days (with a range of 4 to 30 days), while another measured it at 8.2 days on average. At peak effect, patients in one study saw their lung capacity increase by more than 50%, jumping from an average of about 1,845 cc to nearly 2,900 cc. That kind of measurable improvement in breathing capacity reflects what patients experience subjectively: significantly easier breathing and stronger muscles.
If you haven’t seen meaningful improvement by about two weeks, the treatment may not be effective for your particular situation. Not everyone responds equally, and roughly 1 in 5 treatment courses in one study did not produce satisfactory improvement.
How Long the Benefits Last
IVIg is not a permanent fix. The improvement you gain from a single course typically lasts several weeks to a few months. One study measured sustained improvement lasting an average of about 107 days (roughly three and a half months), though individual results varied widely. Some people maintain their gains for only a few weeks, while others benefit for considerably longer.
Because the effects are temporary, IVIg is generally used as a rescue therapy rather than a long-term maintenance treatment. Current treatment guidelines recommend it for specific situations: acute flares of worsening weakness, myasthenic crisis (when breathing becomes dangerously compromised), and sometimes to optimize strength before thymectomy surgery. For ongoing disease control, doctors rely on other immunosuppressive strategies that provide more durable results.
Why It Works This Way
In myasthenia gravis, your immune system produces antibodies that attack receptors at the junction between nerves and muscles, blocking the signals that tell your muscles to contract. IVIg delivers a large dose of pooled antibodies from healthy donors, and these appear to work through several overlapping pathways. They may directly neutralize the harmful antibodies targeting your muscle receptors, reduce your body’s production of those antibodies, and broadly recalibrate immune system activity. The exact balance of these mechanisms isn’t fully understood, which is one reason the response timeline can vary between patients.
What the Infusion Looks Like
A standard course involves infusions given over two to five consecutive days. You’ll sit or recline while the medication is delivered through an IV line, with each session lasting several hours. The total dose is calculated based on your body weight. After the infusion days are complete, you wait for the effects to build over the following week or so.
Factors That Affect Your Response
The type of antibody driving your myasthenia gravis matters. Most people have antibodies targeting the acetylcholine receptor (AChR-positive MG), and these patients tend to respond more reliably to IVIg. A smaller group has MuSK-positive myasthenia gravis, driven by a different antibody type. IVIg is generally less effective for MuSK-positive patients, who often require different treatment approaches.
Disease severity also plays a role. IVIg is typically reserved for moderate to severe flares, and studies evaluating its effectiveness have focused on patients with significant, measurable weakness. For people with milder symptoms, the risk-benefit balance may favor other treatments. The presence of a myasthenic crisis, where breathing is directly threatened, is one of the clearest indications for IVIg (or its alternative, plasma exchange), because the relatively fast onset of action can be genuinely lifesaving.
IVIg Compared to Plasma Exchange
Plasma exchange is the other rapid-acting treatment option for myasthenia gravis flares. It works by physically filtering harmful antibodies out of your blood rather than introducing new ones. Clinical evidence shows that both treatments produce similar levels of improvement, similar durations of benefit, and comparable safety profiles. The choice between them often comes down to practical factors: IV access, availability of equipment, and patient tolerance. IVIg is generally simpler to administer and doesn’t require specialized plasmapheresis equipment, which makes it more accessible in many settings.
Common Side Effects
Headache is the most frequent side effect, affecting more than half of patients who receive IVIg. It can range from mild to severe and usually responds to slowing the infusion rate or taking over-the-counter pain relievers. Other common reactions include fever, chills, and fatigue during or shortly after the infusion. These tend to be self-limiting.
A small percentage of patients (about 0.6 to 1%) develop aseptic meningitis, a more intense headache accompanied by neck stiffness and sensitivity to light. Despite the alarming name, this is an inflammatory reaction rather than an infection, and it resolves on its own. Rare but more serious complications include blood clots and kidney problems, which is why you’re monitored during and after treatment.